Glenmark Pharmaceuticals Initiates Class II Recall for Azelaic Acid Gel Due to CGMP Deviations and Gritty Texture Complaints
Glenmark Pharmaceuticals Inc., USA has initiated a Class II voluntary recall for 13,824 tubes of Azelaic Acid Gel, 15%, citing CGMP deviations related to a gritty texture. This event, stemming from their Goa, India manufacturing facility, demands immediate attention from procurement and regulatory teams to assess supply chain stability and product quality risks for this topical generic.
Glenmark Pharmaceuticals Initiates Class II Recall for Azelaic Acid Gel Due to Quality Concerns
Glenmark Pharmaceuticals Inc., USA, based in Mahwah, NJ, has initiated a voluntary Class II recall for its Azelaic Acid Gel, 15%. This significant action, identified by recall number D-0662-2025 and commenced on September 17, 2025, directly impacts the availability of a key topical treatment for conditions like acne and rosacea within the United States. The core reason for this recall is documented CGMP (Current Good Manufacturing Practice) deviations, specifically driven by market complaints detailing a “gritty texture (grainy)” in the product. This quality defect, affecting batch #19252524 with an expiration date of May 2027, has led to the removal of 13,824 tubes from nationwide distribution. For procurement directors, this means an immediate need to identify and quarantine any existing stock of this specific batch, preventing further distribution and potential patient dissatisfaction or adverse events. Regulatory affairs heads must assess the implications of a Class II classification, which indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This necessitates a thorough review of internal quality systems and supplier agreements to mitigate similar future risks.
Manufacturing Origin and Supply Chain Exposure for Azelaic Acid Gel
The recalled Azelaic Acid Gel, 15% (NDC 68462-626-52), was manufactured by Glenmark Pharmaceuticals Limited at its facility in Colvale-Bardez, Goa 403513, India, for Glenmark Pharmaceuticals Inc., USA. This geographic split in manufacturing and marketing highlights a common global supply chain model, but also exposes inherent risks when quality control falters at the production source. With 13,824 tubes distributed nationwide across the United States now subject to recall, supply chain VPs must evaluate their current inventory levels and potential for localized or broader shortages of Azelaic Acid Gel. This event directly impacts the continuity of supply for a widely used generic dermatological product. Business development executives should note that such a recall can create market opportunities for competitors offering alternative Azelaic Acid formulations or other topical treatments, potentially shifting market share. The incident underscores the imperative for stringent oversight of overseas manufacturing partners, ensuring their adherence to FDA-mandated CGMP standards to prevent disruptions that carry both financial and reputational costs.
Mitigating Future Risks: Proactive Strategies for Topical Generic Sourcing
Given the Class II recall of Azelaic Acid Gel, 15%, procurement directors and supply chain VPs must proactively reassess their sourcing strategies for topical generic pharmaceuticals. While specific alternative suppliers for Azelaic Acid are not detailed in our current intelligence, the broader implication is clear: reliance on a single manufacturing source, particularly one experiencing CGMP deviations, introduces significant vulnerability. Companies should prioritize diversifying their supplier base, engaging with multiple qualified manufacturers across different geographies where feasible. The qualification process for new pharmaceutical suppliers, especially for active pharmaceutical ingredients (APIs) or finished drug products, is extensive, involving rigorous audits, analytical testing, stability studies, and regulatory filings. This can take 12-24 months or longer, emphasizing the need for foresight rather than reactive measures. Regulatory affairs heads must ensure that quality agreements with contract manufacturers are robust, clearly defining responsibilities for quality control, deviation management, and recall procedures. This Glenmark event serves as a critical reminder that a resilient supply chain is built on continuous monitoring and a proactive risk management framework, safeguarding against quality issues that can lead to market withdrawals and impact patient access.